Safety and Immunogenicity of a SARS-CoV-2 MRNA Vaccine (SYS6006) in Minks, Cats, Blue Foxes, and Raccoon Dogs

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Oct 4

PMID 39364147

Authors

Hong Huo

Jinming Wang

Chan Li

Shuang Xiao

Han Wang

Jinying Ge

Gongxun Zhong

Zhiyuan Wen

Chong Wang

Qiaoling Lang

Lili Chen

Zilong Wang

Jinliang Wang

Xijun Wang

Xijun He

Yuntao Guan

Lei Shuai

Zhigao Bu

Affiliations

Soon will be listed here.

Abstract

Minks, cats, and some other species of carnivores are susceptible of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and have a high risk of transmitting SARS-CoV-2 to humans. The development of animal vaccines can be an effective measure to protect animals against SARS-CoV-2 and reduce the potential risk of human infection. We previously developed a messenger ribonucleic acid (mRNA) vaccine SYS6006 that has been proven to be an efficient coronavirus disease 2019 (COVID-19) vaccine widely used in humans. Here, we further evaluated the safety and immunogenicity of SYS6006 as an animal COVID-19 vaccine candidate for SARS-CoV-2 susceptible animals or wild animals. SYS6006 was safe and immunogenic in mice and completely protected mice against mouse-adapted SARS-CoV-2 infection in the upper and lower respiratory tracts. SYS6006 was able to induce neutralizing antibodies against the SARS-CoV-2 wild-type, Delta, and Omicron BA.2 strain on day 7 after prime immunization, and two doses of immunization could enhance the neutralizing antibody responses and produce long-lasting potent antibodies for more than 8 months in minks and cats, blue foxes, and raccoon dogs, while all immunized animals had no abnormal clinical signs during immunization. These results provided here warrant further development of this safe and efficacious mRNA vaccine platform against animal COVID-19.

References

Patel R, Kaki M, Potluri V, Kahar P, Khanna D . A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022; 18(1):2002083. PMC: 8862159. DOI: 10.1080/21645515.2021.2002083. View

Oude Munnink B, Sikkema R, Nieuwenhuijse D, Molenaar R, Munger E, Molenkamp R . Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. 2020; 371(6525):172-177. PMC: 7857398. DOI: 10.1126/science.abe5901. View

Slifka M, Amanna I . How advances in immunology provide insight into improving vaccine efficacy. Vaccine. 2014; 32(25):2948-57. PMC: 4096845. DOI: 10.1016/j.vaccine.2014.03.078. View

Sit T, Brackman C, Ip S, Tam K, Law P, To E . Infection of dogs with SARS-CoV-2. Nature. 2020; 586(7831):776-778. PMC: 7606701. DOI: 10.1038/s41586-020-2334-5. View

Nooruzzaman M, Diel D . Infection Dynamics, Pathogenesis, and Immunity to SARS-CoV-2 in Naturally Susceptible Animal Species. J Immunol. 2023; 211(8):1195-1201. PMC: 10558081. DOI: 10.4049/jimmunol.2300378. View

Puranik A, Lenehan P, Silvert E, Niesen M, Corchado-Garcia J, OHoro J . Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. Med. 2021; 3(1):28-41.e8. PMC: 8664708. DOI: 10.1016/j.medj.2021.12.002. View

Jin F, Qiu Y, Wu Z, Wang Y, Cai C, Fu L . Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial. Vaccine. 2024; 42(7):1561-1570. DOI: 10.1016/j.vaccine.2024.01.098. View

He X, He C, Hong W, Yang J, Wei X . Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. Med Res Rev. 2023; 43(4):932-971. DOI: 10.1002/med.21941. View

Shi Y, Wang G, Cai X, Deng J, Zheng L, Zhu H . An overview of COVID-19. J Zhejiang Univ Sci B. 2020; 21(5):343-360. PMC: 7205601. DOI: 10.1631/jzus.B2000083. View

10.

Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B . Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2. Science. 2020; 368(6494):1016-1020. PMC: 7164390. DOI: 10.1126/science.abb7015. View

11.

Chen G, Qiu Y, Wu K, Wu Y, Wang Y, Zou Y . Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials. Hum Vaccin Immunother. 2023; 19(3):2285089. PMC: 10760391. DOI: 10.1080/21645515.2023.2285089. View

12.

Sila T, Sunghan J, Laochareonsuk W, Surasombatpattana S, Kongkamol C, Ingviya T . Suspected Cat-to-Human Transmission of SARS-CoV-2, Thailand, July-September 2021. Emerg Infect Dis. 2022; 28(7):1485-1488. PMC: 9239874. DOI: 10.3201/eid2807.212605. View

13.

Carabelli A, Peacock T, Thorne L, Harvey W, Hughes J, Peacock S . SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023; 21(3):162-177. PMC: 9847462. DOI: 10.1038/s41579-022-00841-7. View

14.

Zhou Y, Zhi H, Teng Y . The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. J Med Virol. 2022; 95(1):e28138. PMC: 9538491. DOI: 10.1002/jmv.28138. View

15.

Caserta L, Martins M, Butt S, Hollingshead N, Covaleda L, Ahmed S . White-tailed deer () may serve as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern. Proc Natl Acad Sci U S A. 2023; 120(6):e2215067120. PMC: 9963525. DOI: 10.1073/pnas.2215067120. View

16.

Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

17.

Su Y, Qiu Y, Wang Y, Xu Y, Huang C, Zhang Q . Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial. Vaccine. 2024; 42(9):2438-2447. DOI: 10.1016/j.vaccine.2024.03.005. View

18.

Nerpel A, Kasbohrer A, Walzer C, Desvars-Larrive A . Data on SARS-CoV-2 events in animals: Mind the gap!. One Health. 2023; 17:100653. PMC: 10665207. DOI: 10.1016/j.onehlt.2023.100653. View

19.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

20.

Gregorio G, Catacutan A, Perez M, Dans L . Efficacy, Effectiveness, and Safety of COVID-19 Vaccine Compared to Placebo in Preventing COVID-19 Infection among 12-17 Years Old: A Systematic Review. Acta Med Philipp. 2024; 58(7):41-53. PMC: 11168957. DOI: 10.47895/amp.v58i7.7930. View